References
Dacie JV, Lewis SM. Paroxysmal nocturnal hemoglobinuria: clinical manifestations, haematology, and nature of the disease. Ser Haematol. 1972;5:3–23.
Rosse WF. A short history of paroxysmal nocturnal hemoglobinuria: how we came to understand its natural history. In: Omine M, Kinoshita T, eds. Paroxysmal Nocturnal Hemoglobinuria and Related Disorders: Molecular Aspects of Pathogenesis. Tokyo: Springer; 2003:71–83.
Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci USA. 1983;80:5066–5070.
Holguin MH, Fredrick LR, Bernshaw NJ, Wilcox LA, Parker CJ. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest. 1989;84:7–17.
Parker CJ. Historical aspects of paroxysmal nocturnal haemoglobinuria: ‘defining the disease’. Br J Haematol. 2002;117:3–22.
Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73:703–711.
Nagakura S, Ishihara S, Dunn DE, et al. Decreased susceptibility of leukemic cells with PIG-A mutation to natural killer cells in vitro. Blood. 2002;100:1031–1037.
Murakami Y, Kosaka H, Maeda Y, et al. Inefficient response of T lymphocytes to glycosylphosphatidylinositol anchor-negative cells: implications for paroxysmal nocturnal hemoglobinuria. Blood. 2002;100:4116–4122.
Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobin- uria-type cells in bone marrow failure syndrome. Blood. 2002;100:3897–3902.
Inoue N, Murakami Y, Kinoshita T. Molecular genetics of paroxysmal nocturnal hemoglobinuria. Int J Hematol. 2003;77:107–112.
Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci USA. 1999;96: 5209–5214.
Inoue N, Izui T, Kuwayama M, et al. A possible intrinsic mechanism for clonal expansion of PNH abnormal cells. In: Omine M, Kinoshita T, eds. Paroxysmal Nocturnal Hemoglobinuria and Related Disorders: Molecular Aspects of Pathogenesis. Tokyo: Springer; 2003:117–126.
Lewis SM, Dacie JV. The aplastic anaemia-paroxysmal nocturnal haemoglobinuria syndrome. Br J Haematol. 1967;13:236–251.
Tichelli A, Gratwohl A, Wursch A, Nissen C, Speck B. Late haematological complications in severe aplastic anaemia. Br J Haematol 1988;69:413–418.
Nishimura J, Murakami Y, Kinoshita T. Paroxysmal nocturnal hemoglobinuria: an acquired genetic disease. Am J Hematol. 1999;62:175–182.
Griscelli-Bennaceur A, Gluckman E, Scrobohaci ML, et al. Aplastic anemia and paroxysmal nocturnal hemoglobinuria: search for a pathogenetic link. Blood. 1995;85:1354–1363.
Schrezenmeier H, Hertenstein B, Wagner B, Raghavachar A, Heimpel H. A pathogenetic link between aplastic anemia and proxysmal nocturnal hemoglobinuria is suggested by a high frequency of aplastic anemia patients with a deficiency of phos- phatidylinositol glycan anchored proteins. Exp Hematol. 1995;23:81–87.
Azenishi Y, Ueda E, Machii T, et al. CD59-deficient blood cells and PIG-A gene abnormalities in Japanese patients with aplastic anaemia. Br J Haematol. 1999;104:523–529.
Luzzatto L, Nafa K. Genetics of PNH. In: Young NS, Moss J, eds. Paroxysmal Nocturnal Hemoglobinuria and the Glycosylphos- phatidylinositol-Linked Proteins. New York, NY: Academic Press, 2000:21–47.
Parker CJ, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria: Recommendations of the International PNH Interest Group. Blood. In press.
Iwanaga M, Furukawa K, Amenomori T, et al. Paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes. Br J Haematol. 1998;102:465–474.
Dunn DE, Tanawatthnacharoen P, Boccuni P, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Inter Med. 1999;132:401–408.
Feng X, Chuhjo T, Sugimori C, et al. Diazepam-binding inhibitor- related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood. 2004;104:2425–2431.
Bemba M, Guardiola P, Garderet L, et al. Bone marrow transplantation for paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1999;105:366–368.
Raiola AM, Van Lint MT, Lamparelli T, et al. Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. Haematologica. 2000;85:59–62.
Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal haemoglobinuria. N Engl J Med. 1995;333:1253–1258.
Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal diseases of treated aplastic anemia. Semin Hematol. 2000;37:91–101.
Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101:1236–1242.
Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood. 2002;100:3897–3902.
Maciejewski JP, Follmann D, Nakamura R, et al. Incresased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood. 2001;98:3515–3519.
Meyers G, Parker CJ. Management issues in paroxysmal nocturnal hemoglobinuria. Int J Hematol. 2003;77:125–132.
Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003;102:3587–3591.
Nishimura JI, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83:193–207.
Fujioka S, Asai T. Prognostic features of paroxysmal nocturnal hemoglobinuria in Japan. Nippon Ketsueki Gakkai Zasshi. 1989;52:1386–1394.
Socie G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996;348:573–577.
Nishimura J, Phillips KL, Ware RE, et al. Efficient retrovirus-mediated PIG-A gene transfer and stable restoration of GPI-anchored protein expression in cells with the PNH phenotype. Blood. 2002;99:2748–2751.
Parker CJ. An overview of the development of specific inhibitors of complement: opportunities for therapy of paroxysmal nocturnal hemoglobinuria. In Omine M, Kinoshita T, eds. Paroxysmal Nocturnal Hemoglobinuria and Related Disorders: Molecular Aspects of Pathogenesis. Tokyo: Springer; 2003:11–23.
Hillmen PV, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350:552–559.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Omine, M., Kinoshita, T., Nakakuma, H. et al. Paroxysmal Nocturnal Hemoglobinuria. Int J Hematol 82, 417–421 (2005). https://doi.org/10.1532/IJH97.05140
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1532/IJH97.05140